

Anthony M. Masztak, CPA/ABV/CFF, CFE

Curriculum Vitae

Professional History

Gleason IP, a division of Gleason & Associates, Inc. – Managing Director

2007 to Present

Mr. Masztak is a managing director who specializes in project management and financial and economic analysis in intellectual property matters.

Mr. Masztak's experience in intellectual property engagements includes analyzing and quantifying damages in both patent infringement and other intellectual property matters. Mr. Masztak has extensive experience in developing and supporting claims for lost profits and reasonable royalties; evaluating secondary indicia of nonobviousness, including drivers of commercial success and nexus; performing analysis of irreparable harm in preliminary injunction and temporary restraining order hearings; and critiquing damages analyses of other experts. Mr. Masztak also has experience in determining the potential exposure for clients with products that are potentially at risk of infringing another entity's intellectual property. In addition, Mr. Masztak has considerable expertise in reviewing license agreements and analyzing royalty streams. Mr. Masztak's experience spans numerous industries, including pharmaceuticals and life sciences, manufacturing, electronic arts, retail, oil and gas, coal, utilities, hospitality, and others.

Mr. Masztak has more than fifteen years of experience in providing a full range of accounting, consulting, and economic services in the areas of intellectual property, fraud and forensic investigations, litigation support, valuations, and financial reorganization. Mr. Masztak has significant experience in class action litigation, including calculating the potential exposure for clients and using financial and economic analysis to assist in the class certification process. Mr. Masztak has analyzed and discounted lost profits calculations, performed business valuations, and has experience in fraud and forensic matters. Mr. Masztak's financial reorganization consulting experience includes preparation and evaluation of forecasts and budgets, identifying and implementing cost cutting measures to reduce expenses, and analysis of financial reports.

Deloitte & Touche LLP – Manager

2001 - 2007

As a Manager, Mr. Masztak worked with the Assurance and Enterprise Risk Services department. During this time Mr. Masztak served numerous clients in various industries ranging in size from small, privately held companies to large multi-national, Fortune 100 companies, with a range of revenues from \$50 million to \$10 billion.

Education and Certification

Bachelor of Science in Business Administration, concentrated in Accounting, *Magna Cum Laude*,

Duquesne University, 2001

Certified Public Accountant, Pennsylvania, 2002

Certified Fraud Examiner, 2008

Certified in Financial Forensics, 2010

Accredited in Business Valuation, 2011

Professional and Business Affiliations

American Economic Association

American Institute of Certified Public Accountants

Association of Certified Fraud Examiners

Pennsylvania Institute of Certified Public Accountants

ANTHONY M. MASZTAK, CPA/ABV/CFF, CFE
SUMMARY OF EXPERIENCE

Cases In Which Mr. Masztak Provided Expert Testimony

Ingenus Pharmaceuticals, LLC, and Leiutis Pharmaceuticals LLP v. Nexus Pharmaceuticals, Inc. – United States District Court for the Northern District of Illinois – Eastern Division, 2024 (Deposition)

Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC – United States District Court for the District of Delaware, 2024 (Trial)

Galderma Laboratories, L.P. and TCD Royalty Sub LP v. Lupin Inc. and Lupin Limited – United States District Court for the District of Delaware, 2024 (Declaration)

Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC – United States District Court for the District of Delaware, 2024 (Deposition)

Elizabeth Naranjo and Misty Fair v. General Nutrition Corp. – Superior Court of the State of California, County of Alameda, 2019 (Deposition)

Eric Boyington v. Percheron Field Services, LLC – United States District Court for the Western District of Pennsylvania, 2017 (Declaration, Deposition)

Elizabeth Naranjo and Misty Fair v. General Nutrition Corp. – Superior Court of the State of California, County of Alameda, 2017 (Declaration)

Charles Brewer v. General Nutrition Corp. – United States District Court for the Northern District of California, 2015 (Deposition)

Intellectual Property Cases in Which Mr. Masztak Led the Engagement

Mr. Masztak has provided a leadership role in over 100 intellectual property engagements. Mr. Masztak supports counsel in all phases of litigation, including assisting with discovery, depositions, development of case theory, analysis of damages and financial modeling, drafting expert reports, and preparing the witness for testimony, as well as attending and assisting at numerous trials. Mr. Masztak's experience spans numerous industries with a particular focus in pharmaceuticals and life sciences, as well as manufacturing, electronic arts, retail, oil and gas, coal, utilities, hospitality, and others. While many of these matters are subject to confidentiality agreements, the list below is a summary of representative cases in which Mr. Masztak provided leadership in which another member of Gleason IP provided expert testimony.

Nexus Pharmaceuticals, Inc. v. Exela Pharma Sciences, LLC. – United States District Court for the District of Delaware, 2025 (Deposition) [*ephedrine sulfate*, damages]

Takeda Pharmaceuticals U.S.A., Inc., v. Mylan Pharmaceuticals Inc. – United States District Court for the District of Delaware, 2024 (Deposition) [*colchicine*, *Breach of Contract Damages*]

Grünenthal GmbH v. Collegium Pharmaceuticals, Inc. and Collegium NF, LLC. – International Chamber of Commerce International Court of Arbitration, 2024 (Declaration) [*tapentadol*, *Breach of Contract Damages*]

Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc., et al. – United States District Court for the District of Delaware, 2024 (Declaration) [*fingolimod*, *Bond Recovery*]

In Re: Palbociclib Patent Litigation (Pfizer Inc., Warner-Lambert Company LLC, PF Prism C.V., Pfizer Manufacturing Holdings LLC, and PF PRISM IMB B.V. v. Synthon Pharmaceuticals, Inc., Synthon B.V., and Synthon International Holding B.V.) – United States District Court for the District of Delaware, 2023 [*palbociclib*, *Commercial Success*]

Azurity Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC – United States District Court for the District of New Jersey, 2023 [*amlodipine*, *Commercial Success*]

Slayback Pharma LLC v. Eye Therapies, LLC – United States Patent Trial and Appeal Board, 2022, 2023 [*brimonidine*, *Commercial Success*]

Intercept Pharmaceuticals, Inc. and Intercept Pharma Europe Ltd. v. Apotex Inc. and Apotex Corp. – United States District Court for the District of Delaware, 2022 [*obeticholic acid*, *Commercial Success*]

Novartis Pharmaceuticals Corporation v. HEC Pharm Co. Ltd. and HEC Pharm USA Inc. – United States Supreme Court, 2022 [*fingolimod*, *Preliminary Injunction*]

Melinta Therapeutics, LLC, Melinta Subsidiary Corp., and Rempex Pharmaceuticals, Inc. v. Nexus Pharmaceuticals, Inc. – United States District Court for the Northern District of Illinois, 2022 [*minocycline*, *Preliminary Injunction*]

Bial – Portela & CA S.A., Bial – Holdings, S.A., and Sunovion Pharmaceuticals Inc. v. Alkem Laboratories Limited and S&B Pharma, Inc.; and Bial – Portela & CA S.A., Bial – Holding, S.A., and Sunovion Pharmaceuticals Inc. v. Apotex Inc. and Apotex Corp. – United States District Court for the District of Delaware, 2022 [*eslicarbazepine acetate*, *Commercial Success*]

Darren Clevenger and David Bloom on behalf of themselves and all others similarly situated v. Welch Foods Inc., A Cooperative, The Promotion in Motion Companies, Inc., a Delaware Corporation, and Does 1 through 25, inclusive – United States District Court for the Central District of California, 2022 [*Welch's Fruit Snacks*, *Class Action Damages*]

AstraZeneca AB and AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery, LP – United States District Court for the Northern District of West Virginia, 2022 [*budesonide/formoterol, Preliminary Injunction*]

Venn Therapeutics v. Corbus Pharmaceuticals Holdings, Inc. – United States District Court for the Middle District of Florida, 2022 [*antibody CRB-601, Preliminary Injunction*]

Bionpharma Inc. v. CoreRx, Inc. – United States District Court for the Southern District of New York, 2021 [*enalapril, Preliminary Injunction*]

Exela Pharma Sciences, LLC v. Eton Pharmaceuticals, Inc. – United States District Court for the District of Delaware, 2021 [*cysteine hydrochloride, Commercial Success*]

Allergan Sales, LLC and Allergan, Inc. v. Sandoz, Inc. and Alcon Laboratories, Inc. – United States District Court for the District of New Jersey, 2021 [*brimonidine tartrate-timolol maleate, Commercial Success*]

Silvergate Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC – United States District Court for the District of Delaware, 2021 [*enalapril, Commercial Success*]

Cytonome/ST, LLC v. NanoCollect Biomedical, Inc. – United States District Court for the District of Delaware, 2020 [*Cell Sorter Microfluidic Device, Patent Damages*]

UCB, Inc., UCB Pharma GmbH, and LTS Lohmann Therapie-Systeme AG v. Actavis Laboratories UT, Inc. – United States District Court for the District of Delaware, 2020 [*rotigotine, Commercial Success*]

AstraZeneca AB and AstraZeneca Pharmaceuticals LP v. Mylan Pharmaceuticals Inc. and 3M Company – United States District Court for the Northern District of West Virginia, 2020 [*budesonide/formoterol, Commercial Success*]

Actelion Pharmaceuticals Ltd. v. Zydus Pharmaceuticals (USA) Inc., et al. – United States District Court for the District of New Jersey, 2020 [*macitentan, Commercial Success*]

Pfizer Inc., PF Prism C.V., C.P. Pharmaceuticals International C.V., PBG Puerto Rico LLC, and PF Prism IMB B.V. v. Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. – United States District Court for the District of Delaware, 2020 [*tofacitinib, Commercial Success*]

Biogen International GmbH and Biogen MA Inc. v. Sandoz Inc., Princeton Pharmaceutical Inc., MSN Laboratories Private Limited and MSN Pharmaceuticals Inc., Zydus Pharmaceuticals (USA) Inc., Sawai USA, Inc. and Sawai Pharmaceutical Co., Ltd., Aurobindo Pharma U.S.A., Inc. and Aurobindo Pharma USA LLC, Hetero USA Inc., Hetero Labs Limited Unit-III, and Hetero Labs Limited, and Shilpa Medicare Limited – United States District Court for the District of Delaware, 2019 [*dimethyl fumarate, Commercial Success*]

Biogen International GmbH and Biogen MA Inc. v. Mylan Pharmaceuticals, Inc. – United States District Court for the District of West Virginia, 2019 [*dimethyl fumarate, Commercial Success*]

Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Hetero USA Inc., Hetero Labs Limited Unit-V, Hetero Labs Limited, HEC Pharm Co., Ltd., HEC Pharm USA, Inc., Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc., Torrent Pharmaceuticals Ltd., Torrent Pharma Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Limited – United States District Court for the District of Delaware, 2019 [*fingolimod, Preliminary Injunction*]

Astellas Pharma Inc., Astellas US LLC, Astellas Pharma US, Inc., Medivation LLC., Medivation Prostate Therapeutics LLC, and The Regents of The University of California v. Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. – United States District Court for the District of Delaware, 2019 [*enzalutamide, Commercial Success*]

Morphosys AG v. Janssen Biotech, Inc., Genmab US, Inc. and Genmab A/S – United States District Court for the District of Delaware, 2018 [*daratumumab, Commercial Success*]

Hospira, Inc. v. Fresenius Kabi USA, LLC – United States District Court for the Northern District of Illinois, Eastern Division, 2018 [*dexmedetomidine, Commercial Success*]

Ameranth, Inc. v. Pizza Hut, Inc., Pizza Hut of America, Inc. and QuikOrder, Inc. – United States District Court for the District of Southern California, 2018 [*Menu Synchronization Software, Patent Damages*]

Vanda Pharmaceuticals, Inc. v. Inventia Healthcare Pvt. Ltd., Vanda Pharmaceuticals, Inc. v. West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp., Vanda Pharmaceuticals, Inc. v. Lupin Limited and Lupin Pharmaceuticals, Inc. – United States District Court for the District of Delaware, 2017 [*iloperidone, Commercial Success & Irreparable Harm*]

In the Matter of an Arbitration Under the Uncitral Arbitration Rules (1976) Between Phosphagenics Limited and Mylan Laboratories Limited and In the Matter of an Arbitration Under the SIAC Rules Between Phosphagenics Limited and Mylan Laboratories Limited Consolidated Under the Rules of Arbitration of the Singapore International Arbitration Centre (5th Ed, 1 April 2013) – Singapore International Arbitration Centre, 2017 [*daptomycin, Breach of Contract Damages*]

Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc. and Actavis Pharma Inc. – United States District Court for the District of New Jersey, 2017 [*carbidopa-levodopa, Commercial Success*]

Boehringer Ingelheim Pharma GmbH & Co. Kg, Boehringer Ingelheim International GmbH, and Boehringer Ingelheim Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., Mylan Pharmaceuticals Inc., Apotex, Inc., Apotex Corp., and Breckenridge Pharmaceutical, Inc. – United States District Court for the District of New Jersey, 2017 [*dabigatran etexilate, Commercial Success*]

Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc. and Mylan Inc., Akorn, Inc., and InnoPharma, Inc. – United States District Court for the Eastern District of Texas, 2017 [*cyclosporine, Commercial Success*]

Hospira, Inc. v. Amneal Pharmaceuticals, LLC – United States District Court for the District of Delaware, 2017 [*dexmedetomidine, Commercial Success*]

Cosmo Technologies Limited, Valeant Pharmaceuticals International, and Valeant Pharmaceuticals Luxembourg S.A.R.L. v. Lupin Ltd. and Lupin Pharmaceuticals, Inc. and Cosmo Technologies Limited, Valeant Pharmaceuticals International, and Valeant Pharmaceuticals Luxembourg S.A.R.L. v. Mylan Pharmaceuticals, Inc. – United States District Court for the District of Delaware, 2017 [*budesonide, Commercial Success*]

Sebela International Limited, Sebela Ireland Limited, and Sebela Pharmaceuticals, Inc. v. Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries Ltd. and Sebela International Limited, Sebela Ireland Limited, and Sebela Pharmaceuticals, Inc. v. Princeton Pharmaceutical Inc., Solco Healthcare U.S., LLC, and Huahai US Inc. – United States District Court for the District of New Jersey, 2017 [*paroxetine mesylate, Preliminary Injunction*]

Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc. and Akorn Inc. v. Allergan, Inc. – United States Patent Trial and Appeal Board, 2017 [*cyclosporine, Commercial Success*]

Cosmo Technologies Limited, Valeant Pharmaceuticals International, and Valeant Pharmaceuticals Luxembourg S.A.R.L. v. Actavis Laboratories FL, Inc. and Cosmo Technologies Limited, Valeant Pharmaceuticals International, and Valeant Pharmaceuticals Luxembourg S.A.R.L. v. Alvogen Pine Brook, LLC – United States District Court for the District of Delaware, 2017 [*budesonide, Commercial Success*]

In re: Sebela Patent Litigation – (Sebela International, Ltd. v. Actavis Laboratories FL, Inc. Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc., Sebela International, Ltd. v. Princeton Pharmaceutical, Inc. Solco Healthcare U.S., LLC and Huahai US Inc). – United States District Court for the District of New Jersey, 2016 [*paroxetine mesylate, Long-felt But Unmet Need*]

AstraZeneca AB v. Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., Actavis FL Laboratories, Inc., Watson Laboratories, Inc., Wockhardt Bio AG, Wockhardt USA LLC, Sun Pharma Global FZE, Sun Pharmaceuticals Industries Ltd., Mylan Pharmaceuticals, Inc., and Amneal Pharmaceuticals, LLC – United States District Court for the District of Delaware, 2016 [*saxagliptin, Commercial Success*]

Supernus Pharmaceuticals, Inc. v. Actavis, Inc. et al. – United States District Court for the District of New Jersey, 2016 [*topiramate, Commercial Success*]

Supernus Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA), Inc. et al. – United States District Court for the District of New Jersey, 2016 [*topiramate, Commercial Success*]

Hospira, Inc. and Orion Corporation v. Eurohealth International SARL and West-Ward Pharmaceutical Corporation – United States District Court of Delaware, 2016 [*dexmedetomidine, Commercial Success/Non-Infringement*]

Janssen Pharmaceuticals, Inc., Grünenthal GmbH, and Depomed, Inc. v. Actavis Elizabeth LLC and Alkem Laboratories Limited, Janssen Pharmaceuticals, Inc., Grünenthal GmbH, and Depomed, Inc. v. Roxane Laboratories, Inc., Janssen Pharmaceuticals, Inc., Grünenthal GmbH, and Depomed, Inc. v. Alkem Laboratories Limited, Janssen Pharmaceuticals, Inc., Grünenthal GmbH, and Depomed, Inc. v. Actavis Laboratories UT, Inc. – United States District Court for the District of New Jersey, 2015 [*tapentadol hydrochloride, Commercial Success*]

Helsinn Healthcare S.A. and Roche Palo Alto LLC v. Cipla Ltd., Cipla USA, Inc. Eurohealth International Sarl, West-Ward Pharmaceutical Corp., and Mylan Institutional LLC – United States District Court for the District of Delaware, 2015 [*dexmedetomidine, Commercial Success*]

Otsuka Pharmaceutical Co., Ltd. v. Alembic Pharmaceuticals Limited, Alembic Limited, Alembic Global Holdings SA, and Alembic Pharmaceuticals Inc. – United States District Court for the District of New Jersey, 2015 [*aripiprazole, Temporary Restraining Order*]

Shire Development LLC, Shire Pharmaceutical Development Inc., Cosmo Technologies Limited, and Nogra Pharma Limited, v. Cadila Healthcare Limited (d/b/a Zydus Cadila) and Zydus Pharmaceuticals (USA) Inc. – United States District Court for the District of Delaware, 2014 [*mesalamine, Commercial Success*]

Laboratorios Silanes, S.A. De C.V., Instituto Bioclon, S.A. De C.V. and Rare Disease Therapeutics, Inc. v. BTG International, Inc. – United States Patent Trial and Appeal Board, 2014 [*crotalidae polyvalent immune fab, Commercial Success*]

Pfizer, Inc., Wyeth, LLC, Wyeth Pharmaceuticals, Inc., PF Prism, CV v. Apotex, Inc., Apotex Corp., Breckenridge Pharmaceuticals, Inc., Alembic Pharmaceuticals Ltd., Lupin Ltd., Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Mylan, Inc., Roxane Laboratories, Inc., Sandoz, Inc., Watson Laboratories, Inc. Florida, Wockhardt Ltd., Wockhardt USA, LLC, Zydus Pharmaceuticals (USA), LLC, and Cadila Healthcare Limited – United States District Court for the District of Delaware, 2014 [*desvenlafaxine, Commercial Success*]

Apotex, Inc. and Apotex Corp. v. Acorda Therapeutics, Inc. – United States District Court for the Southern District of New York, 2014 [*tizanidine hydrochloride, Breach of Contract Damages*]

Shire LLC, Shire Development, Inc., and Shire Development, LLC v. Amneal Pharmaceuticals, LLC, Roxane Laboratories, Inc., Sandoz, Inc., Mylan, Inc., Mylan Pharmaceuticals, Inc., Actavis, Inc., Actavis, LLC, Actavis Elizabeth LLC, Johnson Matthey, Inc., and Johnson Matthey Pharmaceuticals Materials – United States District Court for the District of New Jersey, 2014 [*lisdexamfetamine, Commercial Success*]

Warner Chilcott Company, LLC v. Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited (d/b/a Cadila Healthcare) – United States District Court for the District of Delaware, 2013 [*mesalamine, Commercial Success*]

Sciele Pharma, Inc., Andrx Corporation, Andrx Pharmaceuticals, Inc. (N/K/A Watson Laboratories, Inc.-Florida), Andrx Pharmaceuticals, L.L.C., Andrx Laboratories (NJ), Inc. Andrx EU Ltd., and Andrx Labs, L.L.C. v. Lupin Ltd. And Lupin Pharmaceuticals, Inc. – United States District Court District of Delaware, 2011 [*metformin hydrochloride, Preliminary Injunction*]

In the Matter of the Arbitration Between Par Pharmaceutical, Inc. and MiddleBrook Pharmaceuticals, Inc. – American Arbitration Association, 2011 (Hearing) [*Development Costs, Breach of Contract Damages*]